Semax is a synthetic peptide developed in the 1980s, derived from a fragment of adrenocorticotropic hormone (ACTH). It is primarily known for its cognitive-enhancing and neuroprotective properties. In clinical practice across Russia and Ukraine, Semax is approved for the treatment of ischemic stroke, cognitive impairments, and optic nerve atrophy.

It is frequently utilized in controlled laboratory environments for studying neurological peptide pathways, receptor signaling, and cellular response mechanisms associated with neurobiological function.

This product is supplied exclusively for laboratory research and must not be used in humans or animals.